Opportunity Information: Apply for CDC RFA GH11 1199
Apply for CDC RFA GH11 1199
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Cooperative Agreement with the South Africa National Health Laboratory Service (NHLS)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.283 Centers for Disease Control and PreventionInvestigations and Technical Assistance.
- This funding opportunity was created on Apr 22, 2011 and posted on Mar 10, 2011.
- Applicants must submit their applications by May 31, 2011 Applicatons are due by 500pm U.S. Eastern Standard Time. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $15,000,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Assistance will be provided only to the South Africa National Health Laboratory Services (NHLS). No other applications are solicited. NHLS is the most appropriate and qualified agency to conduct the activities specified under this cooperative agreement.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity (CDC RFA GH11-1199) is a discretionary cooperative agreement issued by the Centers for Disease Control and Prevention under CFDA 93.283 (CDC Investigations and Technical Assistance). It was designed as a single-award agreement, with an estimated total funding level of $15,000,000. The funding instrument is a cooperative agreement, which typically signals substantial involvement by the CDC in programmatic direction, technical support, and oversight compared with a standard grant. No cost sharing or matching was required. The notice was posted March 10, 2011, created April 22, 2011, and ultimately closed May 31, 2011 at 5:00 pm U.S. Eastern time (originally scheduled to close May 9, 2011). The opportunity was later archived June 30, 2011. While an award ceiling and floor are listed as $0, this generally reflects a posting or formatting convention in older listings rather than an absence of funding, especially given the stated total of $15 million.
Eligibility was restricted to one entity: the South Africa National Health Laboratory Service (NHLS). The announcement explicitly states that assistance would be provided only to NHLS and that no other applications were solicited, describing NHLS as the most appropriate and qualified organization to carry out the activities. In practical terms, this makes the announcement a targeted, sole-eligible recipient cooperative agreement intended to formalize CDC support for a specific national laboratory and public health partner in South Africa rather than a competitive open solicitation.
The core purpose of the cooperative agreement was broad public health systems strengthening and disease control work at a national level in South Africa, centered on three linked functions: (1) conducting public health surveillance and epidemiologic assessments to understand and track conditions driving disease, premature death, and reduced quality of life; (2) developing and improving high-quality laboratory systems and diagnostic capacity; and (3) implementing evidence-based public health programs informed by surveillance and laboratory findings. The scope is intentionally wide, reflecting the central role laboratories play in detection, confirmation, monitoring, and response across many health threats, and positioning NHLS as a backbone institution for national surveillance and response.
Within that broad scope, the announcement highlights infectious diseases as a major emphasis, with particular attention to HIV/AIDS. The HIV/AIDS focus is described in practical, risk-reduction terms and explicitly includes blood safety, injection safety, infection control, and medical waste management, which are critical areas where strong laboratory practice, quality systems, and facility-level standards directly reduce transmission risk and improve patient and healthcare worker safety. Beyond HIV/AIDS, the agreement also encompasses malaria; emerging and re-emerging infectious diseases; zoonotic diseases; neglected tropical diseases; tuberculosis; and influenza and other diseases with pandemic potential. The inclusion of influenza and other pandemic-potential diseases, alongside emergency preparedness and response, signals an intent to bolster early detection and surge capacity, as well as coordinated response mechanisms that rely heavily on laboratory readiness, specimen referral networks, and timely reporting.
The opportunity also extends beyond infectious disease to include environmental health issues, chronic diseases, maternal and child health, reproductive health, injury control and prevention, public health preparedness, and biosafety. This mix suggests a comprehensive public health laboratory and surveillance agenda, where NHLS capacity is expected to support not only outbreak-oriented work but also ongoing population health monitoring and program evaluation. Biosafety is specifically called out, reinforcing the expectation that laboratory expansion and increased diagnostic throughput must be paired with safe handling of pathogens, proper containment practices, and workforce training to protect staff and communities while maintaining confidence in public health operations.
Operationally, the cooperative agreement can be understood as CDC partnering with NHLS to strengthen national surveillance and epidemiology, upgrade laboratory quality and diagnostic services, and translate evidence into public health action across a wide range of priority conditions. The announcement provides a contact point at CDCs Procurement and Grants Office for technical access issues, indicating that full details were provided in the full announcement package (the additional information link noted in the synopsis is inactive in the excerpt).
Frequently Asked Questions (FAQs) - CDC RFA GH11-1199 (CFDA 93.283)
What is CDC RFA GH11-1199?
CDC RFA GH11-1199 is a discretionary funding opportunity from the Centers for Disease Control and Prevention (CDC) issued as a cooperative agreement under CFDA 93.283 (CDC Investigations and Technical Assistance). It was designed to support public health systems strengthening and disease control work in South Africa, with a strong emphasis on surveillance, epidemiology, and laboratory capacity.
What type of funding mechanism is this opportunity?
The funding instrument is a cooperative agreement. This typically means CDC has substantial involvement in programmatic direction, technical support, and oversight compared with a standard grant.
Is this an open competitive solicitation?
No. Eligibility was restricted to a single entity, and the announcement explicitly stated that assistance would be provided only to that entity and that no other applications were solicited.
Who was eligible to apply?
Only the South Africa National Health Laboratory Service (NHLS) was eligible. The opportunity described NHLS as the most appropriate and qualified organization to carry out the activities.
How many awards were expected?
The opportunity was designed as a single-award cooperative agreement, meaning one award to the sole eligible recipient.
What was the estimated total funding level?
The estimated total funding level was $15,000,000.
Why do the award ceiling and floor show $0?
The listing shows an award ceiling and floor of $0, which is generally a posting or formatting convention seen in older listings rather than an indication that no funding was available, especially given the stated estimated total funding level of $15,000,000.
Was cost sharing or matching required?
No. The opportunity stated that no cost sharing or matching was required.
What was the overall purpose of the cooperative agreement?
The core purpose was broad public health systems strengthening and disease control work at a national level in South Africa, centered on surveillance and epidemiologic assessment, improving laboratory systems and diagnostic capacity, and implementing evidence-based public health programs informed by surveillance and laboratory findings.
What are the three main functional areas highlighted in the scope?
The opportunity emphasizes three linked functions: (1) conducting public health surveillance and epidemiologic assessments; (2) developing and improving high-quality laboratory systems and diagnostic capacity; and (3) implementing evidence-based public health programs informed by surveillance and laboratory findings.
Which health topics and diseases were emphasized?
The scope is broad. Infectious diseases are a major emphasis with particular attention to HIV/AIDS. The agreement also encompasses malaria; emerging and re-emerging infectious diseases; zoonotic diseases; neglected tropical diseases; tuberculosis; and influenza and other diseases with pandemic potential. It also includes environmental health issues, chronic diseases, maternal and child health, reproductive health, injury control and prevention, public health preparedness, and biosafety.
How is HIV/AIDS addressed in this opportunity?
The HIV/AIDS focus is described in practical risk-reduction terms and explicitly includes blood safety, injection safety, infection control, and medical waste management. These areas relate directly to reducing transmission risk and improving patient and healthcare worker safety through strong laboratory practice and quality systems.
Why are influenza and other pandemic-potential diseases included?
The inclusion of influenza and other diseases with pandemic potential, alongside emergency preparedness and response, signals an intent to strengthen early detection, surge capacity, and coordinated response mechanisms that rely heavily on laboratory readiness, specimen referral networks, and timely reporting.
What role do laboratories play in this cooperative agreement?
Laboratories are positioned as a backbone institution for national surveillance and response. The scope reflects the role laboratories play in detection, confirmation, monitoring, and response across many health threats, and it emphasizes upgrading laboratory quality systems and diagnostic services to support public health action.
Does the scope cover only infectious diseases?
No. In addition to infectious diseases, the opportunity includes environmental health issues, chronic diseases, maternal and child health, reproductive health, injury control and prevention, public health preparedness, and biosafety, suggesting a comprehensive surveillance and public health laboratory agenda.
Why is biosafety specifically called out?
Biosafety is highlighted to reinforce that expanded laboratory capacity and increased diagnostic throughput should be paired with safe handling of pathogens, proper containment practices, and workforce training to protect staff and communities.
What were the key dates for this funding opportunity?
The notice was posted on March 10, 2011, created on April 22, 2011, and closed on May 31, 2011 at 5:00 pm U.S. Eastern time (it was originally scheduled to close May 9, 2011). The opportunity was later archived on June 30, 2011.
Was the closing date extended?
Yes. The closing date was originally scheduled for May 9, 2011, and it ultimately closed on May 31, 2011 at 5:00 pm U.S. Eastern time.
Is the opportunity still active?
No. The opportunity closed on May 31, 2011 and was archived on June 30, 2011.
What does it mean that this was a targeted, sole-eligible recipient agreement?
It means the announcement was intended to formalize CDC support for a specific national laboratory and public health partner in South Africa (NHLS) rather than to solicit proposals from multiple applicants in a competitive process.
Where was the work intended to take place?
Based on the eligible entity and described national-level objectives, the work was intended to support public health systems strengthening and disease control activities in South Africa through NHLS.
Who was listed as the contact point?
The synopsis referenced a contact point at CDC's Procurement and Grants Office for technical access issues.
Where would applicants have found the full details of the announcement?
The synopsis indicates that full details were available in the full announcement package, but the additional information link referenced in the excerpt was inactive.
What does CFDA 93.283 refer to in this listing?
CFDA 93.283 is the program identifier cited for this opportunity: CDC Investigations and Technical Assistance.
Browse more opportunities from the same category: Health
Next opportunity: Office of Elementary and Secondary Education (OESE) Striving Readers Comprehensive Literacy Grant Program CFDA Number 84.371C
Previous opportunity: OVC FY 11 NCVRW Community Awareness Project
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH11 1199
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH11 1199) also looked into and applied for these:
| Funding Opportunity |
|---|
| Part D Coordinated HIV Services and Access to Research for WICY One Time Supplemental Funds Apply for HRSA 11 094 Funding Number: HRSA 11 094 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Affordable Care Act Program for Early Detection of Certain Medical Conditions Related to Environmental Health Hazards Apply for CDC RFA TS11 1102PPHF11 Funding Number: CDC RFA TS11 1102PPHF11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,500,000 |
| Competitive Revision Applications for NIDCR funded Cooperative Agreements (U01) Apply for PAR 11 144 Funding Number: PAR 11 144 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Centers for Excellence in Clinical Preventive Services (P01) Apply for RFA HS 11 005 Funding Number: RFA HS 11 005 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| The Infant Immune System Implications for Vaccines and Response to Infections (R01) Apply for RFA AI 11 010 Funding Number: RFA AI 11 010 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| International Research in Infectious Diseases, including AIDS (R01) Apply for PAR 11 145 Funding Number: PAR 11 145 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Centers for Education and Research on Therapeutics (CERTs) Scientific Forum (U19) Apply for RFA HS 11 003 Funding Number: RFA HS 11 003 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Centers for Education and Research on Therapeutics (CERTs)( U19) Apply for RFA HS 11 004 Funding Number: RFA HS 11 004 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement to Support State Assessment Initiatives Apply for CDC RFA HK07 70205CONT11 Funding Number: CDC RFA HK07 70205CONT11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| HAITI REHABILITATION AND REINTEGRATION OF PERSONS WITH DISABILITIES PROGRAM Apply for USAID HAITI RFA 521 10 033 Funding Number: USAID HAITI RFA 521 10 033 Agency: Haiti USAID Port Au Prince Category: Health Funding Amount: $9,000,000 |
| NINDS Cooperative Program in Translational Research Single Component Research Projects (U01) Apply for PAR 11 153 Funding Number: PAR 11 153 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Cooperative Program in Translational Research for Resistant Epilepsy and Epileptogenesis (U01) Apply for PAR 11 154 Funding Number: PAR 11 154 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Minority Fellowship Program Apply for SM 11 005 Funding Number: SM 11 005 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $900,000 |
| CDC Mexico Cooperative Agreement for Surveillance, Epidemiology, and Laboratory Capacity Apply for CDC RFA CK11 1106 Funding Number: CDC RFA CK11 1106 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Engaging Indigenous Organizations to Sustain and Enhance Comprehensive HIV/AIDS Services in 26 States of the Federal Republic of Nigeria under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH11 1112 Funding Number: CDC RFA GH11 1112 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $55,000,000 |
| Initiatives Related to the Prevention and Control of Unintentional Injury and Violence Through the World Health Organization (WHO) Apply for CDC RFA CE11 1104 Funding Number: CDC RFA CE11 1104 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Evidence to Action for Strengthened Family Planning and Reproductive Health Services for Women and Girls (E2A) Apply for SOL OAA 11 000041 Funding Number: SOL OAA 11 000041 Agency: Agency for International Development Category: Health Funding Amount: $230,000,000 |
| STRENGTHENING HUMAN RESOURCES FOR HEALTH (HRH) PROGRAM Apply for RFA 663 11 000009 Funding Number: RFA 663 11 000009 Agency: Ethiopia USAID Addis Ababa Category: Health Funding Amount: $55,000,000 |
| Nutrition and Diet in the Causation, Prevention, and Management of Heart Failure (R01) Apply for PA 11 165 Funding Number: PA 11 165 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Nutrition and Diet in the Causation, Prevention, and Management of Heart Failure (R21) Apply for PA 11 166 Funding Number: PA 11 166 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH11 1199", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
